Answers are grounded in this paper and cite their sources.
As compared with interferon alfa, temsirolimus improved overall survival among patients with metastatic renal-cell carcinoma and a poor prognosis. The addition of temsirolimus to interferon did not improve survival. (ClinicalTrials.gov number, NCT00065468 [ClinicalTrials.gov].).
No takes yet. Share an insight, caveat, or question.
Hudes et al. (2007) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: